Trial · NCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177
NCT04949282, Recruiting, Sociedad Española de Medicina Nuclear e Imagen Molecular
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Spanish Series of Patients Treated With the Radionuclide Lutetium177. Trials, record NCT04949282. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04949282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Spanish Series of Patients Treated With the Radionuclide Lutetium177
- NCT number
- NCT04949282
- Status
- Recruiting
- Enrollment
- 5,000 participants, estimated
- Lead sponsor
- Sociedad Española de Medicina Nuclear e Imagen Molecular
- Conditions
Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Neoplasms, Nerve Tissue, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Endocrine Gland Neoplasms, Digestive System Diseases, Gastrointestinal Disease, Intestinal Diseases, Pancreatic Disease, Endocrine System Diseases
- Interventions
- Lutetium [177Lu] oxodotreotide/dotatate, Lutetium [177Lu] oxodotreotide/dotatate
- First posted
- 2021-07-02
- Last updated
- 2022-12-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Up to 12 months | Defined as the time, in months, from Lutathera® treatment initiation to the date of first objective tumour progression, determined according to Response Evaluation Criteria in Solid Tumours (RECIST) Criteria, Version 1.1, or death due to any cause, whichever comes first. |
| Primary | Overall survival (OS) | Up to 12 months | Defined as the time, in months, from Lutathera® treatment initiation to the date of death due to any cause. |
| Primary | Overall response rate (ORR) | Up to 12 months | Is determined by imaging technique according to RECIST criteria v1.1 and is defined as the proportion of treated patients who achieve a best overall response of partial response (PR) or complete response (CR) according to RECIST 1.1 |
| Secondary | Characteristics of the population . | Up to 12 months | Description of the main characteristics of the population studied, treatments received (before and after lutetium) and evolution. |
| Secondary | Adverse Events (AEs) | Up to 12 months | Toxicity will be collected according to grades (NCT-CTCAE) and consequences. |
| Secondary | Prognostic factors | Up to 12 months | Correlation of possible prognostic factors with clinical effectiveness outcomes. |
| Secondary | Areas for improvement care | Up to 12 months | Identification of areas for improvement in the management and selection of patients for treatment with lutathera |
| Secondary | Health-related Quality of Life (HRQoL) | Up to 12 months | Assess the impact of treatment on health-related Quality of Life (HRQoL) by EORTC QLQ-G.I.NET-21 questionnaire.The minimum value ( 1%) and the maximum value (100%), and higher scores mean a better outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 36877234 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04949282
GET https://conductscience.org/api/trials/v1/NCT04949282/registered